ArticleBMC primary care2025
Rationale and design of a prospective study evaluating the prognostic value of lung ultrasound in patients with heart failure in primary care: the EPICAP study protocol.
Article in BMC primary care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung ultrasound (LUS) could detect subclinical congestion and identify patients at increased risk of events. The role of LUS in chronic heart failure (HF) has been widely studied in HF clinics, but little is known about its usefulness in the community. We will assess the prognostic value of LUS in a cohort of chronic HF stable ambulatory patients managed in primary care (PC).
methodsWe will conduct a prospective study with 192 patients at 17 PC centers of the metropolitan area of Barcelona. We will include patients with HF and left ventricular ejection fraction (LVEF) ≥ 50%, with a previous hospital admission for HF decompensation and stable NYHA (New York Heart Association) functional class in the last 3 months. At baseline visit, we will collect demographic and clinical data, and the following issues will be performed: (a) a blood tests, including cardiac biomarkers; (b) a six-minute walking test; (c) a lung ultrasound; (d) a quality of life test Minnesota Living with Heart Failure Test), and (e) frailty tests (Gerontopole and Frailty Index based on the Comprehensive Geriatric Assessment (VGI-index)). LUS will be performed in semisupine position using a 28-area protocol, with a hand-held probe. Follow-up will be carried out every 6 months for 2 years by reviewing medical records and telephone calls. All the events, including HF hospitalizations, cardiovascular death, all-cause death, and visits to PCs and hospital emergencies due to HF will be recorded. After two years another in-office visit will be performed, and all the tests performed at the baseline visit will be repeated. DISCUSSION: The use of LUS in PC centers could improve the monitoring and management of patients with HF by identifying those at higher risk of hospital admission and death.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.